https://www.theblaze.com/news/fluvoxamine-antidepressant-covid-treatment-study?utm_content=buffer38714&utm_medium=referral&utm_source=facebook&utm_campaign=fb-glennbeck&fbclid=IwAR33Gc-r44xN8negfSc2-1-h2cg8cxeB_iebsb3y0FawlsaSbVAe67q_5Ts#toggle-gdpr
$4 generic antidepressant significantly reduces COVID-19 hospitalizations, clinical trial finds
NEWSOctober 28, 2021
APU GOMES/AFP via Getty Images
Like Blaze News? Get the news that matters most delivered directly to your inbox.
An inexpensive, generic antidepressant has been shown to significantly reduce the risk of severe COVID-19 in clinical trials.
Fluvoxamine — a readily available pill used to treat depression and obsessive-compulsive disorder — dramatically reduces serious illness and death from COVID-19 when prescribed early, according to a study published in the journal Lancet Global Health.
There were 1,497 COVID-positive patients in Brazil involved in the study; 741 patients were given fluvoxamine and 756 were given a placebo. The study — which was performed from Jan. 20 until Aug. 5 — found that patients who received fluvoxamine saw their hospitalizations or long-term medical observation rates decrease by nearly one-third.
No comments:
Post a Comment
Your message has been sent to the moderator for approval and shall appear very soon!